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Abstract
Background: Vagal nerve stimulation (VNS) has been approved for treatment-resistant depression. Many antidepressants
increase expression of brain-derived neurotrophic factor (BDNF) in brain or activate, via phosphorylation, its receptor, TrkB.
There have been no studies yet of whether VNS would also cause phosphorylation of TrkB.
Methods: Western blot analysis was used to evaluate the phosphorylation status of TrkB in the hippocampus of rats
administered VNS either acutely or chronically. Acute effects of VNS were compared with those caused by fluoxetine or
desipramine (DMI) whereas its chronic effects were compared with those of sertraline or DMI.
Results: All treatments, given either acutely or chronically, significantly elevated phosphorylation of tyrosines 705 and 816
on TrkB in the hippocampus. However, only VNS increased the phosphorylation of tyrosine 515, with both acute and
chronic administration causing this effect. Pretreatment with K252a, a nonspecific tyrosine kinase inhibitor, blocked the
phosphorylation caused by acute VNS at all three tyrosines. Downstream effectors of Y515, namely Akt and ERK, were also
phosphorylated after acute treatment with VNS, whereas DMI did not cause this effect.
Conclusion: VNS rapidly activates TrkB phosphorylation and this effect persists over time. VNS-induced phosphorylation of
tyrosine 515 is distinct from the effect of standard antidepressant drugs.
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Introduction
Neurotrophins, particularly brain-derived neurotrophic factor
(BDNF), are key molecules regulating neuronal survival, develop-
ment, function and plasticity [1]. BDNF binding to its receptor,
TrkB [2], results in receptor dimerization and autophosphory-
lation in the kinase domain of its cytosolic region, followed by
activation of various signaling pathways. Specific signaling is
promoted by phosphorylation of other tyrosine residues so as to
create docking sites for adapter proteins that couple the receptors
to intracellular signal transduction mechanisms. Autophosphory-
lation of the TrkB catalytic domain at tyrosine 705 is considered a
critical step in TrkB receptor activation, which further regulates
the phosphorylation and activation of other tyrosines, of which
tyrosines 515 and 816 are most extensively studied [2,3].
Phosphorylation of Y515 leads to activation of Ras/mitogen
activated protein kinase (Ras/MAPK) and phosphoinositide 3-
kinases (PI3K) signaling pathways, whereas phosphorylation of
tyrosine 816 induces activation of the phospholipase C- c1 (PLC-
c1)-mediated signaling pathway [2].
The neurotrophic hypothesis of depression and antidepressant
action arose from evidence suggesting that BDNF levels are
reduced in mood disorders [4,5,6] and that chronic antidepressant
treatment enhances BDNF expression and signaling [7,8,9].
Although chronic treatment with antidepressants is required to
increase the expression of BDNF message [10,11] or protein
[6,12], acute antidepressant treatment can rapidly activate TrkB
receptors. Available evidence indicate that shortly after single
administration of different classes of antidepressants to mice, there
was increased phosphorylation of TrkB receptors in cerebral
cortex and the hippocampus [13,14]. Two tyrosines were found to
be phosphorylated, Y705 and Y816. Moreover, Saarelainen et al.
[14] found that signaling via the TrkB receptor is required for a
behavioral response typically induced by antidepressants. In
particular, they showed that administration of antidepressants to
transgenic mice over-expressing the truncated TrkB-T1 isoform,
which lacks the functional cytosolic signaling domain, does not
produce less immobility in the forced swim test (FST).
Vagal nerve stimulation (VNS) has been approved by the Food
and Drugs Administration (FDA) for treatment-resistant epilepsy
(1997) and treatment-resistant depression (TRD) (2005). Over long
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reducing the severity of symptoms in patients with TRD
[15,16,17,18]. When given repeatedly to animals, VNS has been
shown to activate both noradrenergic and serotonergic cell body
areas [19,20]. Behaviorally, Krahl et al. [21] reported that 30 min
per day of VNS for 4 days significantly reduced immobility in the
FST, i.e., it had antidepressant-like activity. We have shown
recently that its administration chronically (14 days) also causes
antidepressant-like activity in the FST that is not seen in rats with
lesions of serotonergic neurons [22]. Given the possible involve-
ment of BDNF in antidepressant action, some investigators have
begun to examine the effect of VNS on BDNF message. VNS
given for just three hours increased message for BDNF in rat
hippocampus and cerebral cortex [23] and this has also been seen
in hippocampus after chronic VNS [24]. There have been no
studies though examining the effect of either acute or repeated
administration of VNS on the phosphorylation of TrkB in rat
brain. We hypothesized that both acute and repeated VNS would
increase the phosphorylation of the tyrosines at Y705 and Y816,
similar to what has been found with antidepressants. This was
observed but in addition another tyrosine, Y515, was found to be
phosphorylated as well.
Materials and Methods
Experiments were carried out using adult male Sprague-Dawley
rats, 250–350 g (Harlan). Rats were group housed and maintained
in a temperature-controlled environment on a 14:10 h light-dark
cycle and had access to food and water ad libitum. Experimental
protocols were approved by the IACUC in accordance with the
guidelines of the Public Health Service, American Physiological
Society, and the Society for Neuroscience.
Implantation of vagal nerve stimulators
Vagus nerve electrodes were implanted on the vagus nerve
under aseptic conditions. The surgical procedure was similar to
that described by Cunningham et al. [25] except that the
anesthetic was a mixture of 75 mg/kg ketamine and 0.5 mg/kg
medetomidine. Briefly, the coil electrode was placed around the
left cervical vagus nerve and carotid sinus ventral to the carotid
bifurcation. The bipolar stimulating electrode was configured with
the cathode at the proximal lead and the anode at the distal lead to
preferentially direct action potential propagation toward the
central nervous system by creating an anodal block at the distal
lead. The electrodes were connected to a stimulator pack
(Cyberonics, Inc., Houston TX) and placed in a subcutaneous
pouch on the back of the rat. Rats that received VNS were
instrumented with an operational stimulator pack that was
programmed by a handheld computer. Control rats received a
dummy simulator pack that was the same size and weight (48 mm
633 mm 67.1 mm; 16 g). The rat was injected with penicillin
immediately post-op and topical antibiotic applied to the wound.
Rats were monitored during recovery under a heat lamp until fully
ambulatory. Beginning 7 days after surgery, VNS was turned on
for either 2 hours (acute) or 14 days (chronic). The stimulation
paradigm consisted of one burst of 20 Hz, 250 msec pulse width,
250 mA current for 30 sec every 5 min. These parameters are the
initial parameters used in clinical studies [15,16]. Also, we found
that doubling the current used to 500 mA caused autonomic
changes in blood pressure and heart rate (data not shown). For
both the acute and the chronic studies, VNS stimulation occurred
until the rats were sacrificed.
Implantation of Osmotic Minipumps
This was done exactly as described previously [26] except that
the pumps delivered fluid intraperitoneally rather than subcuta-
neously. One day prior to surgery, osmotic minipumps delivering
5 ml/h (Model 2ML2, DURECT Corporation, Cupertino, CA)
were filled with drug or vehicle, filtered through 0.9-mm
nitrocellulose filters (Millipore, Bedford, MA) using a sterile
technique in an air-filtered hood. Drug solution concentrations
were determined based on the mean rat weight over the 14 days of
treatment. Either a dose of 7.5 mg/kg/day of sertraline or 10 mg/
kg/day desipramine produced serum concentrations in the
therapeutic range [26,27]. The vehicle solution consisted of 10%
EtOH/0.9% NaCl [28]. Minipumps were stored in sealed
containers filled with sterile saline in a 30–32uC incubator to
prime the pumps until the time of surgery. At the time of surgery,
rats were anesthetized with an intramuscular injection of a mixture
of 75 mg/kg ketamine and 0.5 mg/kg medetomidine. A drug-
filled minipump was implanted intraperitoneally via a midline
incision made on the lower abdomen. After the pump was
implanted, the muscle and skin were sutured. The rat was injected
with penicillin immediately post-op and topical antibiotic applied
to the wound. Rats were monitored during recovery under a heat
lamp until fully ambulatory.
Intracerebroventricular (i.c.v) administration of K252a
Rats were administered K252a (Calbiochem, San Diego, CA).
K252a is a nonspecific tyrosine kinase inhibitor [29] that has been
shown to block autophosphorylation of TrkB and inhibit many
biological functions of BDNF [30]. The total dose administered of
either neurotoxin was 10 mgi n1 0ml of saline or PBS containing
1% DMSO. When administered intracerebroventricularlyat this
dose, Benmansour et al. [31] found that it blocked the effect of
exogenously administered BDNF on serotonin clearance. Control
rats were injected with vehicle. Rats were anesthetized with a
mixture of 75 mg/kg ketamine and 0.5 mg/kg medetomidine and
placed into a stereotaxic frame. K252a was administered i.c.vwith
stereotaxic coordinates, AP, 20.8 mm from Bregma; ML,
+1.4 mm from midline; DV, 24.0 mm from dura [31] using a
28-gauge stainless steel injector attached to a Bee Syringe Pump
(Bioanalytical System Inc, West Lafayette, IN, USA) at a rate of
1 mL/min. Once the infusion was completed, the injector was left
in place for an additional 5 min to allow diffusion of vehicle or
K252a.
Western blot analysis
Rats were sacrificed by rapid decapitation, brains quickly
removed and hippocampi were dissected out on an ice-cooled
dish. Samples were stored at 280uC until processed for Western
blot analysis. Samples were homogenized in a lysis buffer (50 mM
Tris, 1 mM EDTA, 0.35% NA Deoxycholate, 150 mM NaCl, 1%
Igepal, H2O, and 10 ml of protease inhibitor mixture (Sigma) per
100 mg tissue), incubated on ice for 30 min and then centrifuged
(13000 g, 15 min). Protein levels of the collected supernates were
measured using the Bradford assay (Biorad, Hercules, CA).
Proteins were separated in a SDS-PAGE gel and blotted onto a
nitrocellulose membrane. Membranes were incubated at 4uC
overnight with the following primary antibodies: anti-phoshoY515
(1:1000 in 1% BSA in TBST, Abcam, Cambridge, MA), anti-
phoshoY705 (1:1000 in 1% BSA in TBST, Abcam, Cambridge,
MA), anti-phoshoY816 (1:4000 in 1% BSA in TBST, Abcam), and
anti-TrkB (1:10000 in 1% BSA in TBST, Neuromics, Edina, MN),
anti-phoshoAkt (Ser473; 1:1000 in 5% BSA in TBST, Cell
Signaling Technology, Inc., Danvers, MA), anti-phoshoAkt
(Thr308; 1:1000 in 5% BSA in TBST, Cell Signaling Technology,
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tion, Carmarillo, CA), anti-p44/42 MAPK (Erk1/2; 1:2000 in 5%
BSA in TBST, Cell Signaling Technology, Inc.), anti-phosho-p42/
44 MAPK (pERK1/2, Thr202/Tyr204; 1:1000 in 5% BSA in
TBST, Cell Signaling Technology, Inc.). Equal loading was
confirmed using anti-b-actin (1:100,000 in 1% BSA in TBST,
Sigma), which was routinely used for normalization. Membranes
were washed with TBS/0.1% Tween (TBST) and incubated with
horseradish peroxidase conjugated secondary antibody (1:5000 in
1% BSA in TBST, Sigma). Secondary antibodies were visualized
using enhanced chemiluminescence kits (Pierce, Rockford, IL)
followed by an exposure to X-ray film for detection.
Results were calculated as the ratio of phosphorylated TrkB at
specific tyrosines to total TrkB, and are shown graphically as the
percent of the sham VNS or vehicle value in the VNS studies and
as the percentage of the control saline value for the antidepressant
studies. Total TrkB did not change after either acute or chronic
VNS or drugs as shown by the ratio of total TrkB/b-actin.
Similarly, the ratios of phosphorylated Akt and ERK at specific
amino acid residues to total Akt and ERK, respectively, are shown
graphically as the percentage of the respective control group as
mentioned above.
Statistical analysis
Immunoblot bands were quantified using NIH ImageJ1.32. In
experiments without K252a, data were analyzed using one-way
multivariate analysis of variance (MANOVA) followed by
Student’s Newman-Keuls post-hoc tests. In experiments with
K252a pretreatment, data were analyzed using a two-way
MANOVA followed by Student’s Newman-Keuls post-hoc tests.
MANOVA was used as all three phosphorylation sites reside on
the same protein and therefore are not independent measures.
VNS data were analyzed separately from drug data. P ,0.05 was
considered significant. All data are presented as the mean
+/2
SEM percentage of control values.
Results
In the first experiment, the effect of acute (2 hr) VNS on TrkB
phosphorylation was compared with that produced by acute
administration of a selective serotonin reuptake inhibitor (SSRI),
fluoxetine (15 mg/kg, i.p), and a selective norepinephrine reuptake
inhibitor (NRI), desipramine (10 mg/kg, i.p) (Figure 1). The drugs
were administered 2 hours prior to obtaining brain tissue.
Multivariate ANOVAs were carried out separately either for
VNS treatment or for drug treatment. For the antidepressant data,
there was a significant main effect of treatment for tyrosine 705
[F(2,9)=17.35, p,0.001] and for tyrosine 816 [F(2,9)=17.35,
p,0.001] but not for tyrosine 515 [F(2,9)=0.28, p.0.05]. As
expected [13,14], post-hoc analysis revealed that acute administra-
tion of either fluoxetine or DMI caused a significant increase in
phosphorylation of tyrosines 705 and 816 in the hippocampus
compared to that measured in vehicle-treated rats (Figure 1).
Acute administration of VNS did this also. Unexpectedly, acute
VNS also significantly increased the phosphorylation of tyrosine
515 [F(1,13)=16.21, p,0.01] (Figure 1). Total TrkB protein levels
were not altered after either acute antidepressant or VNS
treatment (Figure 1), e.g., the ratio of total TrkB/b-actin for the
sham group was not significantly different from that in the VNS
group (100
+/21.25 vs. 104.03
+/24.87, respectively, P.0.05).
Given the importance of prolonged antidepressant and VNS
treatments for optimal clinical response in depression, the next
experiment examined the effect of longer administration, for 14
days, of VNS, sertraline (7.5 mg/kg/day, i.p) or DMI (10 mg/kg/
day, i.p) on the phosphorylation of TrkB. The results were similar
to what was seen acutely, namely the drugs and VNS significantly
increased phosphorylation at Y705 [for drugs, F(2,15)=7.98,
p,0.01; for VNS, F(1,16)=38.97, p,0.001] and Y816 [for drugs,
F(2,15)=15.39, p,0.001]; for VNS, F(1,16)=10.58, p,0.01] but
only VNS increased phosphorylation of Y515 [F(1,16)=8.83,
p,0.01] (Figure 2). Western blot analyses revealed that total TrkB
protein levels were not altered after either chronic antidepressant
or VNS treatment when compared with that measured in the
control group (Figure 2).
Since VNS is able to induce phosphorylation of TrkB at all
three tyrosines (i.e. tyrosines 705, 816 and 515) and that the
phosphorylation of tyrosine 515 is distinct from the effect of
antidepressant drugs, there may be some differences in the
mechanisms by which VNS and antidepressant drugs cause such
effects. To determine whether VNS was causing tyrosine 515 to be
phosphorylated through a mechanism not directly involving TrkB
activation, i.e., not involving the autophosphorylation site, we
tested the effect of an agent that prevents tyrosine kinase activity,
K252a. It was administered intracerebroventricularly for 2 hours
before the start of VNS, which was then given for 2 hours. K252a
pretreatment blocked the effects of VNS on TrkB phosphorylation
at all three tyrosines, namely Y705, Y816 and Y515 (Figure 3).
Two-factor MANOVA showed a significant interaction between
inhibitor x treatment for tyrosine 705 [F(1,14)=6.98, p,0.05] for
tyrosine 816 [F(1,14)=5.24, p,0.05], and for tyrosine 515
[F(1,14)=12.61, p,0.01]. Post-hoc analysis revealed that admin-
istration of K252a alone did not alter TrkB phosphorylation in
comparison to that measured in rats pretreated with vehicle. Total
TrkB protein levels were not altered (Figure 3).
Because of the VNS-induced phosphorylation of Y515,
subsequent experiments compared the effect of VNS to that
produced by DMI on phosphorylation of proteins downstream of
the 515 site on TrkB, namely Akt and ERK2 [2,32]. As shown in
Figure 4A, VNS given for two hours significantly increased the
phosphorylation of pERK2 and this effect was reduced, but not
completely blocked, by prior i.c.v administration of K252a. The
results of the two-way ANOVA analysis showed a significant main
effect of VNS [F(1, 24)=145.5, p,0.001] and K252a [F(1,
24)=18.5, p,0.001] as well as a significant interaction between
VNS and K252a [F(1, 24)=19.14, p,0.001]. By contrast, DMI
(10 mg/kg, i.p) treatment did not significantly increase pERK2
(p=0.72) (Fig. 4B).
Similar results were obtained for the two phosphorylation site
sites on Akt, namely S475 and T308 (Figure 5A). Two-factor
MANOVA analysis revealed a significant main effect of VNS [for
S475, F(1, 24)=49.38, p,0.001; for T308, F(1, 24)=17.50,
p,0.001] as well as K252a [for S475, F(1, 24)=26.82, p,0.001;
for T308, F(1, 24)=34.38, p,0.001]. A significant interaction was
also found between VNS and K252a [for S475, F(1, 24)=26.82,
p,0.001; for T308, F(1, 24)=34.38, p,0.001]. Post hoc analysis
indicated VNS caused significant increases in phosphorylation of
both S475 and T308. In this case, though, K252a produced a
complete, rather than partial, blockade of the effect of VNS
(Figure 5A). As before, DMI did not significantly increase
phosphorylation of either residue [for S475, F(1, 10)=3.31,
p.0.05; for T308, F(1, 10)=0.35, p=0.56] (Figure 5B).
Discussion
The most interesting finding in this study is that both acute and
chronic VNS administration not only increased phosphorylation
of the TrkB receptor at Y705 and Y816 but at Y515 also. In
confirmation of previous work carried out using mice [13,14], we
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phosphorylation of this receptor at Y707 and Y816 but not at
Y515. Thus, among antidepressant treatments evaluated to date,
the phosphorylation of Y515 caused by VNS is unique. Similar
TrkB protein levels were observed across all treatment groups
when compared with control groups thus discounting the
possibility that changes in phosphorylation were due to alterations
in TrkB protein levels. Stimulation of the TrkB receptor activates
several intracellular signaling cascades that can be regulated
independently of each other; among them, the MAPK, PI3K and
PLC-c1 pathways are best characterized [2]. The present study
revealed that acute and chronic treatments of rats with VNS
increased TrkB receptor phosphorylation at sites that can activate
PLC-c1 and MAPK/PI3K signal transduction pathways. Pre-
treatment with K252a blocked this effect of VNS. Consistent with
the phosphorylation of Y515, VNS increased phosphorylation of
its downstream effectors ERK and Akt and this effect was also
reduced or blocked by K252a. By contrast, both acute and chronic
administration of standard antidepressants such as sertraline and
DMI induced phosphorylation of TrkB receptor at the site linked
to PLC-c1 signaling without altering the MAPK/PI3K pathway
and DMI treatment did not increase phosphorylation of ERK or
Akt.
Figure 1. Vagal nerve stimulation (VNS) rapidly induces TrkB activation in rat hippocampus. Effects of acute (2 hr) VNS, desipramine
(DMI, 10 mg/kg, i.p) or fluoxetine (15 mg/kg, i.p) on TrkB phosphorylation at different tyrosine residues in rat hippocampus.Phospho-TrkB values are
normalized against total-TrkB values. One-way MANOVA, Student’s Newman-Keuls post-hoc test, *P,0.05, n=428 per group.
doi:10.1371/journal.pone.0034844.g001
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mRNA levels of BDNF [23] and BDNF protein [24] in rat
hippocampus. However, as the majority of brain BDNF is
intracellular [33], total brain BDNF does not reliably reflect its
release. Only a small amount of total tissue BDNF is released upon
activation of neurons [33,34] such that only a small fraction is
available to activate TrkB receptors. Consequently, to provide
another measure of drug effects on BDNF function, the
phosphorylation state of the TrkB receptor has been measured
using Western blot analysis with site-directed antibodies. Changes
in the phosphorylation status of TrkB occur upon antidepressant
administration to mice. Saarelainen et al. [14] and Rantamaki et
al. [13] reported that 30–120 min after administration of either
imipramine, fluoxetine, citalopram, reboxetine or moclobemide,
phosphorylation of TrkB at Y705 and Y816 in mouse brain
increased significantly. The initial report [14] had this effect being
most pronounced in the anterior cingulate cortex rather than in
the hippocampus but the subsequent report [13] found it in the
hippocampus as well. Similar to what was observed in mice, the
present study indicates that acute administration of fluoxetine or
DMI also increased phosphorylation of TrkB at these tyrosines in
rat hippocampus. In addition, acute VNS administration also
significantly increased phosphorylation of TrkB at Y515. Thus,
both acute administration of standard antidepressants and VNS
phosphorylate TrkB at a site linked to increased PLC-c1 signaling,
whereas only acute VNS phosphorylated the tyrosine linked to
MAPK/PI3K signal transduction.
Further experiments were carried out to examine downstream
signaling linked to Y515 such as phosphorylation of both Akt (at
serine 473 and threonine 308) and ERK1/2 (at threonine 202 for
ERK1 and Tyr204 for ERK2) in total hippocampus. VNS
treatment consistently caused an increase in phosphorylation of
Figure 2. Vagal nerve stimulation (VNS) induces TrkB activation in rat hippocampus. Effects of chronic (14 days) VNS, desipramine (DMI,
10 mg/kg/day, i.p) or sertraline (7.5 mg/kg/day, i.p) on TrkB phosphorylation at different tyrosine residues in rat hippocampus.Phospho-TrkB values
are normalized against total-TrkB values. One-way MANOVA, Student’s Newman-Keuls post-hoc test, *P,0.05, n=6210 per group.
doi:10.1371/journal.pone.0034844.g002
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increase in Akt and ERK phosphorylation. Further studies using
immunohistochemical detection instead of western blot analysis is
needed to address whether or not DMI could potentially cause a
more selective pattern of activation of specific subregions within
hippocampus.
If BDNF were mediating the effect of antidepressants, one
might expect all three tyrosines to be phosphorylated. It is often
assumed that the signaling molecule causing the increase in
antidepressant-induced phosphorylation of TrkB is BDNF. How-
ever, a recent study by Rantamaki et al. [35] indicates that
antidepressants activate TrkB receptors in the mouse brain in a
manner independent of BDNF. In particular, they showed that in
conditional mutant mice lacking BDNF in the forebrain, acute
administration of imipramine was still able to cause phosphory-
lation of Y816, albeit to a lesser extent than that in wild-type mice.
It was concluded that antidepressants transactivate TrkB receptors
in forebrain independently of BDNF. This conclusion is perhaps
not surprising since, in cells in culture, BDNF causes phosphor-
ylation of TrkB at all three sites [36,37] and stimulates signal
transduction pathways mediated by activation of Y816 and Y515
[36,37,38]. Also, infusion of BDNF into the dentate gyrus of rats
increased activation of ERK2 at 15 min and 3 hours [39].
However, as VNS increases phosphorylation of all three
tyrosines and, in addition, induces the phosphorylation of Akt/
ERK known to be coupled to Y515, it still remains possible that
BDNF (and/or NT-4) is mediating its effect on TrkB. In addition,
it is possible that VNS increases TrkB signaling by mechanisms in
addition to its influencing BDNF or NT-4 release. Increased
intracellular cAMP [40,41] or membrane depolarization [41,42]
have been shown to increase membrane surface expression of
TrkB thus enhancing the ability of BDNF to induce TrkB
autophosphorylation. Furthermore, some G-protein-coupled re-
ceptors have been shown to transactivate TrkB receptors
independently of BDNF [43,44,45]. Finally, as NT-3 (and NT-
4/5) is a low-affinity ligand for TrkB, VNS may induce TrkB
activation by enhancing the effects of this neurotrophin [46].
Whether these molecular mechanisms are involved in VNS-
induced TrkB activation remains to be elucidated.
It is also possible that the effects of VNS could be ligand-
mediated, whereas the effects of DMI could potentially be
mediated by transactivation of TrkB through G-protein coupled
Figure 3. K252a inhibits VNS-induced TrkB phosphorylation in rat hippocampus. The ability of acute (2 hr) VNS to induce phosphorylation
of TrkB was abolished by prior i.c.v administration ofK252a. Phospho-TrkB values are normalized against total-TrkB values. Two-way MANOVA,
Student’s Newman-Keuls post-hoc test, *P,0.05, n=426 per group.
doi:10.1371/journal.pone.0034844.g003
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preferentially blocks norepinephrine transporters [47] leading to
enhanced noradrenergic activity and activation of noradrenergic
receptors. It is known that GPCRs can directly activate ERK/
MAP kinases [48] or mediate transactivation of Trks in the central
nervous system [44,49]. With regard to the hippocampus, studies
in vitro have shown that norepinephrine application in cultured
hippocampal neurons is able to induce TrkB phosphorylation and
downstream signaling (activation of ERK and PI3-K) via GPCR
transactivation of TrkB [50]. However, that study has not
addressed specifically which tyrosine sites were activated within
TrkB and also differ from our in vivo approach. Cultured neurons
lack all the physiological inputs that could be responsible for the
mechanisms by which TrkB is differentially activated.
Other possible mechanisms underlying this difference between
the effects of the antidepressants and VNS include membrane
surface expression of TrkB isoforms. Alternative splicing of the
TrkB pre-mRNA from its locus on DNA yields two isoforms [51].
One is a full-length form of TrkB, TK+, which has the cytosolic
tyrosine kinase domain. The other is the tyrosine kinase lacking
isoform, TK2, which consists of two isoforms, T1 and T2. These
truncated isoforms contain the same extracellular and transmem-
brane domains but different C-terminal sequences. T1 is capable
of binding to BDNF to the same level as TK+ [52] and is
hypothesized to block TK+ functions, such as TK+ phosphory-
lation, by forming heterodimers with TK+ [53,54]. Transgenic
mice over-expressing T1 receptors in brain have reduced TrkB
phosphorylation and are resistant to effects of antidepressants in
the FST [14]. These data indicate that activation of TrkB plays a
role in the antidepressant-induced behavioral effects and that T1 is
able to block such functions. Moreover, T1 has been shown to
have its own signaling pathway that involves the PLC-IP3 pathway
[55]. In addition, there is a difference in intracellular localization
of TK+ and T1. In adult brains, TK+ is localized in both pre- and
postsynaptic regions [56,57,58] whereas T1 is concentrated in the
presynaptic region [56,57]. Du et al. [59] showed that electrical
stimulation facilitated the movement of TrkB from the intracel-
lular pool to the cell surface, particularly in dendrites. Trk
receptors in signaling endosomes activate signaling events that are
different from those activated on the cell surface [60,61]. Hence, it
is possible that antidepressants and VNS produce different
activity-dependent enhancement of TrkB signaling.
K252a, an alkaloid-like compound isolated from Nocardiopsis,i s
frequently used as a nonspecific protein kinase inhibitor for
blocking Trk activity. It was first described as an inhibitor of
protein kinase C [62]. However, Koizumi et al. [63] demonstrated
that it could inhibit Trk-dependent actions at a concentration that
did not block the PKC-dependent action. A subsequent paper
established that K252a could inhibit tyrosine kinase activity of Trk
receptors [64]. K252a also inhibits other classes of tyrosine kinase
receptors, as well as Ser/Thr kinases, including those in the
MAPK cascade [65]. K252a and its analogs appears to interact
directly with the tyrosine-specific protein kinase domain of the
neurotrophin receptors [29]. K252a has been shown to block
autophosphorylation of TrkB and inhibit many biological func-
tions of BDNF [30]. When administered intracerebroventricularly
at the same dose we used, Benmansour et al. [31] found that it
blocked the inhibitory effect of exogenously administered BDNF
on serotonin clearance, as measured by chronoamperometry.
Interestingly, Shirayama et al. [66] showed that local administra-
tion of K252a into the hippocampus blocked the antidepressant-
like effects of BDNF, also locally administered into the
Figure 4. Effects of acute (2 h) VNS (A) or DMI administration (B) on ERK phosphorylation in rat hippocampus. Phospho-ERK2 values
are normalized against total ERK2 values. Data were analyzed by two-way ANOVA followed by Student’s Newman-Keuls post-hoc test. *Significantly
different from corresponding control value, P,0.05. #Significantly different from VNS value in vehicle group, P,0.05, n=7 per group for VNS and 6
per group for DMI. The upper bands seen in the representative images correspond to pERK1 or ERK1 and were not analyzed due to poor
immunoreactivity of pERK1.
doi:10.1371/journal.pone.0034844.g004
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found that i.c.v administration of K252a blocked the effects of
VNS on TrkB phosphorylation. Whether inhibition of TrkB
phosphorylation by K252a would interfere with behavioral effects
of VNS is an important outstanding question.
In conclusion, VNS phosphorylates tyrosine 515 on TrkB and
also the activation of effectors coupled to this Y515 site (Akt/
ERK), and this effect is distinct from those phosphorylated by
standard antidepressant drugs. What role, if any, this plays in the
behavioral effect of VNS remains to be clarified by future
experiments.
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